Amit Dayal, an analyst from H.C. Wainwright, maintained the Buy rating on BioHarvest Sciences. The associated price target remains the same with $14.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amit Dayal has given his Buy rating due to a combination of factors that highlight BioHarvest Sciences’ promising trajectory. The company has shown significant revenue growth, with a 41% year-over-year increase in the second quarter of 2025, and has managed to improve its gross profit margins to nearly 60%, surpassing expectations. Despite a net loss, the company is on track to achieve positive adjusted EBITDA by the fourth quarter of 2025, driven by cost efficiencies and strategic management of potential tariff challenges.
BioHarvest Sciences is poised for future growth through the expansion of its product lines and sales channels. The company plans to launch a new hydration product and expand its Direct-to-Doctor and Health Pros sales channels, which are expected to contribute significantly to future revenues. Additionally, the Health Pros affiliate program aims to onboard 300 professionals, potentially representing a substantial portion of the business. The company’s innovative product development and robust sales strategies position it well to capitalize on the increasing consumer focus on health and wellness, making it an attractive investment opportunity.